Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system

Project description

Innovative cure for thymus deficiency

The thymus plays a critical role in immune system development and its absence at birth leads to severe immunodeficiency, with affected infants typically having a short life expectancy. Thymus tissue transplantation is the only current cure, but it carries a 30 % mortality rate and high costs. The EIC-funded i-THYMUS project proposes a revolutionary solution by using gene therapy to create thymus organoids from the patient’s own cells, which can be implanted through minimally invasive procedures. The approach has yielded promising preclinical data and the aim is to obtain clinical validation through trials by 2028 with a pharmaceutical partner. The project will initially target DiGeorge syndrome but the technology aims to treat other patients including those with thymus damage after chemotherapy.

Objective

Each year, >250 babies are born without a thymus. These babies have a life expectancy of 2-3 years. The only cure is transplantation of thymus tissue, but this has a 30% mortality rate and costs almost >€2.5M. We developed i-Thymus, a revolutionary cure based on the patient’s own cells leveraging innovative gene therapy to generate thymus organoids that can be implanted minimally invasively in the patient (Fig. 1). We have already shown this works in functional proof of concept in vivo. With this EIC Accelerator, we will finalise development to enter the clinic for a Phase I/II trial, to enter the EU market with a pharma partner by 2028. After rapid market entry with ODD for complete DiGeorge syndrome, we will leverage this clinical success and our first revenues to develop i-Thymus for unmet needs of hundreds of thousands of other patients, starting with AML patients who have lost thymus function after high-dose chemotherapy for stem cell transplantation.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

GENEWITY BV
Net EU contribution
€ 2 495 510,93
Address
DE LIMES 7
2342 DH Leiden
Netherlands
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 565 015,61

Participants (1)